MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR COMPOSITIONS FOR LYMPHOMA THERAPY

摘要

A composition comprising one or more selective inhibitors of a mitogen activated protein kinase (MAPK), which exert potent activity against malignant hematopoietic neoplasms such as lymphoid neoplasms that show over-expression and constituative activation of enzymes in the MAPK family. A composition is also provided comprising at least one selective inhibitor of a mitogen activated protein kinase, and at least one selective inhibitor of a Bcl-2 protein. The compositions can be used for targeted lymphoma therapy by administering the compositions in therapeutic effective amounts to treat malignant lymphoid neoplasms.